The number and size of circulating blood cells is the result of an interplay between genetic and environmental factors. The Blood Cell Consortium (BCX) explored the genetic architecture of the three major blood cell types – red blood cells, white blood cells and platelets, including cell-subtype counts in over 100,000 multi-ethnic individuals. It was found […]
First in HumanTherapeutic Clinical trial reveals early promise for treatment for Friedreich’s ataxia
Friedreich’s ataxia is an inherited, progressive neuromuscular disease caused by partial inactivation of the frataxin gene. In this proof-of-concept study of epigenetic modification, carried out in the NIHR/Wellcome Imperial Clinical Research Facility, Prof Richard Festenstein and colleagues demonstrated that inhibition of histone deacetylase activity by high dose nicotinamide increases Frataxin to the levels found in […]
Birth asphyxia is a serious condition which results from lack of oxygen to a newborn child. Oxygen deprivation can happen during birth and – if it lasts long enough – it can cause brain damage. It is responsible for almost a quarter of all neonatal deaths worldwide. Brain hypothermia involves cooling a baby to around […]
Infertility affects one in six couples in the UK. The inability to have children can be devastating, and has important implications for mental, social and reproductive health. By identifying the key factors which control the reproductive function we can improve therapies for infertility.
In the absence of a HIV vaccine, one of the most effective ways of preventing HIV infection is pre-exposure prophylaxis (PrEP) – HIV negative individuals, who are at risk of infection, take prophylactic antiretroviral therapy. This is in the form of a pill which contains two medicines that are also used to treat HIV. If […]
Harnessing world-leading discovery science and clinical expertise to develop innovative therapeutics, devices and diagnostics for healthcare
The NIHR Imperial Biomedical Research Centre (BRC) is a translational research partnership between Imperial College London and Imperial College Healthcare NHS Trust. It provides the infrastructure – human and technological – to conduct early stage experimental medicine within our Academic Health Science Centre. The BRC aims to exploit the scientific power of the College’s Faculties of Medicine, Engineering and Natural Sciences, and provide proof-of-principle of new breakthroughs within the clinical setting. We collaborate extensively with industry, other funding agencies, and with colleagues across the NIHR infrastructure. Our patients and volunteers are closely involved in the design and delivery of research, and the BRC invests heavily in skills and training for the clinical academics of tomorrow.
Examples of research projects testing out new drugs, devices and diagnostics in humans for the first time. The BRC is specifically aimed at supporting these kinds of experimental medicine studies.
The NIHR Imperial BRC has developed a range of innovative device technologies, in collaboration with scientists in our Faculties of Natural Sciences and Engineering. Some of the most recent are highlighted here.
A selection of short films explaining more about key parts of the BRC infrastructure and some of the innovative directions our research is moving into.